Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes.

Journal Article (Journal Article)

The revised International Prognostic Scoring System (IPSS-R) was developed in a cohort of untreated myelodysplastic syndromes (MDS) patients. A French Prognostic Scoring System (FPSS) was recently reported to identify differential survival among azacitidine-treated patients with high-risk MDS. We applied the FPSS and IPSS-R to 150 patients previously randomized to azacitidine monotherapy or a combination of azacitidine with entinostat (a histone deacetylase inhibitor). Neither score predicted response but both discriminated patients with different overall survival (OS; median OS, FPSS: 9·7, 14·7, and 25·3 months, P = 0·018; IPSS-R: 12·5, 11·3, 20·8, and 36 months, P = 0·005). Statistical analysis suggested no improvement in OS prediction for the FPSS over the IPSS-R in azacitidine-treated patients.

Full Text

Duke Authors

Cited Authors

  • Zeidan, AM; Lee, J-W; Prebet, T; Greenberg, P; Sun, Z; Juckett, M; Smith, MR; Paietta, E; Gabrilove, J; Erba, HP; Tallman, MS; Gore, SD; Eastern Cooperative Oncology Group (ECOG) and North American Leukemia intergroup,

Published Date

  • August 2014

Published In

Volume / Issue

  • 166 / 3

Start / End Page

  • 352 - 359

PubMed ID

  • 24712482

Pubmed Central ID

  • PMC4299460

Electronic International Standard Serial Number (EISSN)

  • 1365-2141

Digital Object Identifier (DOI)

  • 10.1111/bjh.12884


  • eng

Conference Location

  • England